Newronika announced today that it received FDA investigational device exemption (IDE) for its deep brain stimulation (DBS) system. The IDE enables Newronika to initiate a pivotal U.S. clinical ...

Movano Health (Nasdaq: MOVE) announced today that it has commenced a blood pressure clinical trial with its newly developed cuffless blood pressure wrist wearable. The study, which is expected to ...

"We have learned a great deal since our last clinical trial in November 2024 and have refined the use of our proprietary cuffless blood pressure wearable in order to extract higher fidelity data ...

Movano (MOVE) has commenced a blood pressure clinical trial with its newly developed cuffless blood pressure wrist wearable. The study, which is expected to be completed during the second week of ...

Movano Health (Nasdaq:MOVE) announced today that it commenced a blood pressure clinical trial with its new cuffless wrist wearable. Pleasanton, California-based Movano designed its updated device ...

Luckily, the remedy is simple: unfurl your beanies, bros of the world, and opt for a cuffless toque or a skull cap beanie instead. The North Face Amazon Arc'Teryx REI Skull caps, for example ...

Existing cuffless BP estimation techniques face limitations such as limited feature extraction capabilities, which can result in lower performance, and validation on nonstandard or small datasets, ...

Yet, in many cases, the answer is much more complex. There is no single reason why an FDA-cleared OTC cuffless blood pressure measurement solution is unavailable in the marketplace today.

Background: Novel smartwatch-based cuffless blood pressure (BP) measuring devices are coming to market and receive FDA and CE labels. These devices are often insufficiently validated for clinical use.